Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Twist Bioscience, Neogene Therapeutics Partner to Develop Personalized CAR T Cells, TCR Therapies

Twist Bioscience, Neogene Therapeutics Partner to Develop Personalized CAR T Cells, TCR Therapies

Oct 13, 2020
|
staff reporter

NEW YORK – Twist Bioscience and Neogene Therapeutics said on Tuesday that they have formed a broad strategic partnership to develop personalized chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies for patients with cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Another Cold Case Arrest

A 50-year-old cold case was cracked using genetic genealogy, the New York Times reports.

Circumventing that Pesky Poison

NPR reports that some insect pests are now becoming resistant to Bt crops.

Not Convened

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

Nature Papers Describe Future Path for Human Genomic Research, Method to Analyze RNA Structure With Nanopore Sequencing, More

In Nature this week: a framework for future human genomic research, PORE-cupine approach to study RNA structure using nanopore sequencing, and more.

What's Popular?

In Business News

  1. Biodesix Prices $72M IPO

  2. UPDATE: Biocartis, Exact Sciences Terminate Oncotype DX Agreement

  3. Exact Sciences Aiming to Make Pan-Cancer Blood Screening Part of Standard Medical Care

    Premium

  4. Agena Bioscience Gets FDA Emergency Use Authorization for MassArray Coronavirus Test

  5. Qiagen Reports 26 Percent Q3 Revenue Growth; Ups Full-Year Guidance

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.